http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#Head
http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#assertion
http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#provenance
http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#pubinfo
http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#assertion
http://purl.obolibrary.org/obo/DOID_9538
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_9538
http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB09331
http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#association
http://www.w3.org/2000/01/rdf-schema#label
darzalex is indicated in combination with bortezomib melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor as monotherapy for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor pi and an immunomodulatory agent or who are double refractory to a pi and an immunomodulatory agent darzalex is a cd38 directed cytolytic antibody indicated in combination with bortezomib melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor as monotherapy for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor pi and an immunomodulatory agent or who are double refractory to a pi and an immunomodulatory agent 1
http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB09331
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#provenance
http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#pubinfo
http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#sig
http://purl.org/nanopub/x/hasSignature
W87Ykj7wWgb+O9M9lwPLu9faZ7KvyGzXMiu4hbMaA5rdWBehXMCMQ9oXYRJ7cWQ1MrWpUajUnIu6iy7dpDV9AtwDBPD9Cz1CdIa3gbK1YUUv9CMbgFI0HrMJoqrX6xYdw3CXa92s7QqIUROH/gzk3j5Dibk3YEGR8AhiNX8OezA=
http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw
http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw
http://purl.org/dc/terms/created
2021-06-12T12:46:02.775+02:00
http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs